Superficial radiation therapy may serve as promising cutaneous MCT treatment

Sensus Healthcare Inc, a manufacturer of medical devices for non-surgical skin cancer and keloid scar treatment, announced that a study published in the Journal of the American Veterinary Medical Association¹ has demonstrated that the company’s superficial radiation therapy SRT-100 system has potential effectiveness and safety for treating cutaneous mast Cell tumors (MCTs) in pets.

The Sensus SRT-100 superficial x-ray unit used to treat all patients involved in this study (All images photo courtesy of Sensus Healthcare Inc).

Traditionally, the treatment for cutaneous MCT treatment has involved surgery or chemotherapy. However, this limited retrospective case series analyzed the use of SRT as a non-invasive alternative for pets with MCT on the head. The results showed SRT treatment achieved a complete response in all cases that completed the intended protocol, with no significant adverse events reported.¹

"The results of this limited retrospective case series are encouraging and demonstrate the potential of SRT-100 as a treatment option for MCTs,” stated Tiffany W. Martin, DVM, MS DACVR(RO), Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, in a company release.²

The study’s objective was to report preliminary findings of hypofractionated superficial radiotherapy for treatment of cutaneous mast cell tumors (MCTs) and report the acute and late toxicity connected with its use. Superficial radiation therapy was effective in the limited study population, and patients had minimal side effects for treatment of cutaneous MCTs.

Patient that suffered from 2 mast cell tumors (MCTs; asterisk) on the lower eyelid and muzzle. Surgical option for the MCT of the eyelid was presented as enucleation.

Joe Sardano, chairman and CEO of Sensus Healthcare, added, in the release, “This study provides further evidence of the efficacy and safety of SRT. We're looking forward to bringing this non-invasive and cost-effective treatment option for the pet industry to market. Providing a less harmful radiation source with fabulous outcomes is of utmost concern to pet owners.

“SRT is mobile,” Sardano continued. “It can be placed in a mobile van to service several veterinary clinics in various sections of a community, region, or state. Treatments are fast and efficient for the vets to administer and extremely cost effective compared to higher energy and more costly devices.”¹

References

1. Martin TW, Prebble A, Leary D. Superficial kilovoltage x-ray radiotherapy for the treatment of cutaneous mast cell tumors on the head in three dogs and one cat: a limited retrospective case series. J Am Vet Med Assoc. 2023 Apr 28:1-6. doi: 10.2460/javma.23.02.0080.
2. Sensus Healthcare's SRT treatment shows promise in treating cutaneous mast cell tumors among pet patients. News release. Sensus Healthcare Inc. May 17, 2023. Accessed May 17, 2023. https://www.globenewswire.com/news-release/2023/05/17/2670946/0/en/Sensus-Healthcare-s-SRT-Treatment-Shows-Promise-in-Treating-Cutaneous-Mast-Cell-Tumors-Among-Pet-Patients.html